Passage BIO (PASG) Net Cash Flow (2019 - 2026)
Passage BIO (PASG) posted quarterly Net Cash Flow of -$13.0 million for Q1 2026, down 150.29% year-over-year from $25.8 million in Q1 2025, and down 100.42% quarter-over-quarter from -$6.5 million in Q4 2025.
Passage BIO (PASG) Net Cash Flow (2019 - 2026) Analysis & Trends
Passage BIO's Net Cash Flow history runs 8 years deep, the most recent figure standing at -$13.0 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 150.29% year-over-year to -$13.0 million; the TTM figure through Mar 2026 stood at -$30.0 million (down 212.98% YoY), while the FY2025 annual figure was $8.7 million, down 44.97% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$13.0 million, down from -$6.5 million in the prior quarter.
- The five-year high for Net Cash Flow was $25.8 million in Q1 2025, with the low at -$28.6 million in Q3 2022.
- The 5-year median for Net Cash Flow is -$5.7 million (2025), against an average of -$5.6 million.
- Peak annual rise in Net Cash Flow reached 1325.71% in 2024, while the deepest fall reached 278.64% in 2024.
- Passage BIO's Net Cash Flow stood at -$28.0 million in 2022, then jumped by 57.56% to -$11.9 million in 2023, then soared by 144.49% to $5.3 million in 2024, then tumbled by 222.51% to -$6.5 million in 2025, then plunged by 100.42% to -$13.0 million in 2026.
- Business Quant data shows PASG's Net Cash Flow at -$13.0 million in Q1 2026, -$6.5 million in Q4 2025, and -$4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | -9.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.18 Mn |
| Jun 30, 2026 | -9.18 Mn |
| Mar 31, 2026 | -12.97 Mn |
| Mar 31, 2026 | -12.97 Mn |
| Dec 31, 2025 | -6.47 Mn |
| Dec 31, 2025 | -6.47 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Jun 30, 2025 | -5.75 Mn |
| Jun 30, 2025 | -5.75 Mn |
| Mar 31, 2025 | 25.78 Mn |
| Mar 31, 2025 | 25.78 Mn |
| Dec 31, 2024 | 5.28 Mn |
| Dec 31, 2024 | 5.28 Mn |
| Sep 30, 2024 | 7.52 Mn |
| Sep 30, 2024 | 7.52 Mn |
| Jun 30, 2024 | -12.00 Mn |
| Jun 30, 2024 | -12.00 Mn |
| Mar 31, 2024 | 15.06 Mn |
| Mar 31, 2024 | 15.06 Mn |